The challenge isn’t just “more paperwork”. IVDR changes what good looks like: stronger performance evidence, tougher classification logic, and (for most IVDs) mandatory involvement with a Notified Body. That combination is exactly why specialised IVD consultancy has gone from “nice to have” to “this is how we keep our portfolio on the EU market”.
This article explains what an IVD consultant actually does, outlines proven IVDR compliance strategies, and helps you decide when external support is essential versus when you can sensibly keep it in-house.
What is IVD consultancy?
IVD consultancy is specialised regulatory, quality, and scientific support, focused specifically on in vitro diagnostic devices under Regulation (EU) 2017/746 (IVDR).
It’s different from general medical device consulting because IVDR has its own “physics”:
- A risk-based IVD classification system (Classes A–D) with different evidence and oversight expectations than MDR devices.
- Performance evaluation as a lifecycle activity, not a one-off “submit and forget” event (Annex XIII).
- Notified Body involvement for most IVDs (practically speaking: everything except certain Class A cases).
So what does an IVD consultant help with, in plain terms?
- IVDR gap assessments against Annex II (technical documentation), Annex III (PMS), and Annex XIII (performance evaluation).
- IVD classification and conformity route analysis (including borderline and “this will be reclassified in review” risks)
- Technical documentation structure, content, and traceability (claims → evidence → labelling → risk)
- Performance evaluation strategy and PER support (scientific validity, analytical performance, clinical performance)
- QMS alignment (typically ISO 13485-based) for IVDR PMS, vigilance, and ongoing updates
- Notified Body engagement: submission quality, Q&A cycles, nonconformity responses, change control
IVD consultancy becomes critical when:
- You’re transitioning legacy IVDD devices to IVDR
- You have Class C/D devices and can’t afford weak PERs or late rework
- Your in-house team is strong – but stretched thin across multiple jurisdictions and deadlines
Why IVDR compliance is so challenging
IVDR didn’t just tweak the rules. It changed the operating model.
Under Regulation (EU) 2017/746, classification is risk-based, performance evaluation is explicit and structured, and the system expects continuous evidence generation and post-market updates.
One big structural shock is oversight capacity. Under IVDR, Notified Bodies are involved in the conformity assessment for the majority of IVDs, because only limited categories can self-declare without NB involvement. That means:
- More manufacturers are competing for fewer review “slots”
- Review cycles tend to be longer
- The cost of getting it wrong is higher (because rework happens inside a queue)
That’s why IVDR compliance strategies matter. They’re not corporate jargon – they’re how you triage effort and reduce “surprise reclassification + missing evidence + NB bottleneck” pain.
External reference: The legal foundation is the IVDR itself: Regulation (EU) 2017/746.
Core IVDR compliance strategies for IVD manufacturers
Strategy 1: Start with a robust IVDR gap assessment
This is the least glamorous strategy, and also the one that prevents expensive chaos later.
A good IVDR gap assessment:
- Compares your current file set against Annex II (technical documentation), Annex III (PMS), and Annex XIII (performance evaluation).
- Flags classification changes and conformity route implications
- Identifies PER evidence gaps (and whether they’re “paper gaps” or “real data gaps”)
- Exposes QMS misalignment (especially PMS/vigilance interfaces and traceability)
Then it does the most important thing: it turns findings into a prioritised plan. Not everything has to be fixed at once, but the right things must be fixed first.
A practical prioritisation model that Patient Guard often uses in IVD consultancy:
- Risk class (C/D first)
- Revenue/patient impact (what must stay on market)
- Evidence gap size (quick wins vs “we need a study”)
- Notified Body dependency (when you must book capacity)
Strategy 2: Confirm correct IVD classification early
Misclassification is one of the most common and costly IVDR mistakes because it cascades into:
- The wrong conformity route
- The wrong performance evidence plan
- The wrong Notified Body expectations
- And the wrong timeline assumptions
Classification is driven by intended purpose and impact on patient management and public health. IVDR classification guidance is refined and revised over time through MDCG outputs, so relying on “what we did under IVDD” is… optimistic.
A useful anchor for your team is the MDCG classification guidance ecosystem (and its revisions). MedTech Europe, for example, has tracked updates and revisions to MDCG 2020-16 related guidance.
Practical move: pressure-test classification with Notified Body expectations early. The goal is to avoid “We built a Class B file… and it’s actually Class C” during review.
Strategy 3: Strengthen performance evaluation
It’s important to treat it like a product, not a document. Under Annex XIII, performance evaluation has three pillars:
- Scientific validity
- Analytical performance
- Clinical performance
And importantly: this is lifecycle-based. A PER is not just a compilation exercise; it’s a structured argument that your intended purpose and performance claims are supported by evidence, and that post-market learning feeds back into the story.
Common gaps we see in legacy transitions:
- Clinical performance evidence is thin, outdated, or not aligned to intended use
- Performance claims exist in marketing or IFU language but aren’t supported by robust data
- Literature is used without a strong appraisal method or relevance justification
- The linkage between performance claims and risk controls is weak
Good IVD consultancy helps you rebuild the logic chain:
Intended purpose → performance claims → evidence plan → evidence appraisal → conclusions → PMS/PMPF updates
(If that chain breaks anywhere, Notified Bodies tend to notice. They’re quite good at noticing… they’re actually annoyingly good.)
The role of an IVD consultant across the IVDR lifecycle
Think of a capable consultant as “regulatory systems engineering”: they connect quality, evidence, and submission strategy so your file behaves coherently in review.
Pre-submission and transition planning
A strong transition plan usually includes:
- Portfolio segmentation: transition vs redevelop vs withdraw
- Transitional provisions planning (and the reality that “extensions” don’t remove the need to do the work)
- Timelines aligned to NB capacity and likely review cycles
- A device-by-device evidence strategy (PER maturity is rarely uniform across a portfolio)
External reference: The European Commission’s medical devices regulations pages and implementation updates are the best “official pulse” for IVDR context and guidance signposting.
Technical documentation and QMS alignment
Here’s where many teams get stuck: they treat technical documentation as a “Regulatory deliverable” and QMS as a “Quality deliverable”.
IVDR expects these to be integrated:
- Risk management ↔ performance evaluation ↔ PMS
- Change control ↔ updates to claims, IFU, PER, and post-market plans
- Vigilance ↔ trending ↔ corrective action ↔ PER updates
Your ISO 13485 QMS can support this beautifully, but only if your procedures clearly define responsibilities, inputs/outputs, and update triggers.
Notified Body engagement
A consultant’s job here is not magic, but disciplined submission hygiene:
- Reducing avoidable questions by making files readable, traceable, and internally consistent
- Preparing structured responses to NB questions and nonconformities
- Keeping change control clean during review cycles
Post-market surveillance and vigilance
Under IVDR, PMS and PMPF aren’t side quests. They’re part of the lifecycle evidence engine.
An IVD consultant typically supports:
- PMS plans that actually match the device’s risk class and real-world use
- PMPF plans that close evidence gaps (not just “we will monitor complaints”)
- Vigilance reporting integration into the QMS
- Post-market data feeding PER updates (so the “lifecycle” claim is real)
Common IVDR pitfalls an IVD consultancy helps you avoid
Let’s name the usual suspects:
- Assuming IVDD evidence is “close enough”
- Underestimating the scale and structure of performance evaluation
- Engaging Notified Bodies too late (or without a strategy)
- Fragmented documentation: claims in one place, evidence in another, risk controls somewhere else entirely
- No clear lifecycle update triggers (so your PER quietly goes stale)
Structured consultancy reduces:
- Rework
- Review cycles
- Market disruption
- And the specific kind of team burnout that comes from answering the same NB question three times because the file still isn’t saying what you think it’s saying
Choosing the right IVD consultancy partner
Not all consultants are created equal. Some are excellent, whereas some are basically a Word template with a billing rate.
What to look for
- Demonstrated IVDR experience (not generic MDR with “we can do IVDs too”)
- Real performance evaluation expertise (scientific validity + analytical + clinical)
- Evidence of Notified Body interaction experience (and not just “we submitted once”)
- A structured methodology: scope, deliverables, timelines, responsibilities
- Clear approach to knowledge transfer (so you’re not dependent forever)
Red flags
- “Guaranteed fast certification” (no one controls NB timelines)
- Generic ISO-only approaches that ignore performance evaluation depth
- No IVD-specific case studies or examples
- Vague scope, vague deliverables, vague everything (except the invoice)
How Patient Guard supports IVDR compliance
Patient Guard operates as a specialist IVD consultancy designed for real-world IVDR constraints. Some of these include limited NB capacity, evidence gaps, and the need for sustainable post-market processes.
Typical support includes:
- IVDR gap assessments and transition roadmaps
- Performance evaluation (PER) strategy and documentation support
- Technical documentation build/repair with traceability mapping
- ISO 13485 + IVDR-aligned QMS implementation (especially PMS/vigilance integration)
- Ongoing post-market and regulatory support as devices evolve
This is meant to be a long-term compliance system, not a one-off “panic sprint” before an audit.
If your PER and PMS don’t clearly “talk” to each other yet, that’s a good moment to bring in an IVD consultant before it becomes a Notified Body comment.
Book a consultation
IVDR compliance timelines and what to do next
IVDR timelines and transitional provisions can create a false sense of safety. Extensions can protect market continuity in theory, but they don’t solve:
- Evidence gaps
- NB capacity constraints
- The time it takes to generate performance data properly
- The time it takes to rebuild a QMS interface around PMS and performance evaluation
So your decision framework is brutally simple:
- Do nothing → high regulatory and commercial risk
- Partial internal effort → moderate risk (often with hidden bottlenecks)
- Structured IVDR compliance strategies with IVD consultancy → controlled, manageable risk
External reference: Keep an eye on the European Commission’s medical devices regulations hub for implementation updates and guidance signposting.
Conclusion
IVDR compliance is not a one-off regulatory event; it’s a lifecycle commitment. The manufacturers who succeed are the ones who treat performance evaluation, PMS, and QMS integration as a living system, not a pile of documents.
A specialist IVD consultancy helps you do three things well:
- Build a credible evidence story (PER done properly)
- Make your documentation traceable and review-friendly
- Keep compliance sustainable after certification, through post-market reality
Contact Patient Guard to develop tailored IVDR compliance strategies for your IVD portfolio.
FAQ
An IVD consultancy supports IVDR classification, gap assessments, technical documentation, performance evaluation (PER), QMS alignment (often ISO 13485-based), and Notified Body engagement across the device lifecycle.
Engage early if you’re transitioning legacy IVDD devices, have Class C/D IVDs, face performance evidence gaps, or need a realistic plan around Notified Body timelines.
It depends on risk class, evidence maturity, and NB availability. The “real time” is usually driven by performance evidence generation and review cycles, not just document writing.
Challenges are usually weak clinical performance evidence, outdated or unstructured scientific validity rationale, and poor traceability between claims, evidence, and post-market plans.
IVDR is performance-evaluation centric (Annex XIII) and classification-driven (A–D) in a way that’s materially different from MDR clinical evaluation structures.
Yes. Patient Guard provides end-to-end IVD consultancy, including transition planning, PER and technical documentation support, QMS alignment, and Notified Body interaction support.
Patient Guards Recent Posts
IVDR Transitional Provisions: 2026 Milestones
2026 represents a significant milestone for the amended IVDR transitional provisions framework.
Cosmetics Product Information File: UK & EU Guide
If you sell cosmetics in the UK or EU, you are legally required to maintain a Cosmetics Product Information File – even if you’re a tiny indie brand mixing batches between client emails.
ISO 15223-1:2025: Your labels may be non-compliant
ISO 15223-1:2025 is the kind of update that looks “small” on paper and then detonates in an audit because it’s printed on every box you ship.
